No Data
No Data
No Data
No Data
No Data
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation For Darovasertib In Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
Oral presentation at ASCO 2024 scheduled for Monday, June 3, 2024, at 9:51 AM CDTThe abstract summary will be available on Thursday, May 23, 2024 at ~5:00pm ETSOUTH SAN FRANCISCO, Calif., April 24, 20
BenzingaApr 24 22:06
IDEAYA Biosciences Has Selected Move-Forward Phase 2 Expansion Dose For IDE397 Monotherapy In MTAP-Deletion Squamous Non-small Cell Lung Cancer, Based On The Adverse Event Profile And Preliminary Clinical Efficacy
Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on AE profile and preliminary clinical efficacy observed, including multiple partial respon
BenzingaApr 22 18:02
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer
Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on AE profile and preliminary clinical efficacy observed, including multiple partial responses by RECIST 1.1
PRNewswireApr 22 18:00
IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
PR NewswireApr 5 18:00
IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
PR NewswireApr 1 18:00
IDEAYA Biosciences Is Maintained at Buy by Citigroup
IDEAYA Biosciences Is Maintained at Buy by Citigroup
Dow JonesMar 22 00:26
No Data
No Data